US009409922B2

(12) **United States Patent**
**Peese et al.**

(10) **Patent No.: US 9,409,922 B2**
(45) **Date of Patent: Aug. 9, 2016**

(54) **IMIDAZOPYRIDINE MACROCYCLES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION**

(71) Applicant: **Bristol-Myers Squibb Company**, Princeton, NJ (US)

(72) Inventors: **Kevin Peese**, Haddam, CT (US); **Zhongyu Wang**, Tolland, CT (US); **John F. Kadow**, Wallingford, CT (US); **Prasanna Sivaprakasam**, Middletown, CT (US); **B. Narasimhulu Naidu**, Durham, CT (US)

(73) Assignee: **Bristol-Myers Squibb Company**, Princeton, NJ (US)

( * ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/619,213**

(22) Filed: **Feb. 11, 2015**

(65) **Prior Publication Data**

US 2015/0232480 A1 Aug. 20, 2015

**Related U.S. Application Data**

(60) Provisional application No. 61/941,004, filed on Feb. 18, 2014.

(51) **Int. Cl.**
***C07D 471/04*** (2006.01)
***C07D 498/22*** (2006.01)

(52) **U.S. Cl.**
CPC ..... ***C07D 498/22*** (2013.01); ***C07D 471/04*** (2013.01)

(58) **Field of Classification Search**
CPC ..... C07D 471/04; C07D 498/22
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

8,906,929 B2 12/2014 Naidu et al.
2010/0130737 A1* 5/2010 Itoh ..... A61K 31/195 544/165

FOREIGN PATENT DOCUMENTS

| | | | |
|---|---|---|---|
| WO | WO 2010/130034 | A1 | 11/2010 |
| WO | WO 2014/028384 | A1 | 2/2014 |
| WO | WO 2014/159076 | A1 | 10/2014 |
| WO | WO 2014/164409 | A1 | 10/2014 |
| WO | WO 2014/164428 | A1 | 10/2014 |
| WO | WO 2015/123182 | A1 | 8/2015 |
| WO | WO 2015/123230 | A1 | 8/2015 |
| WO | WO 2015/126737 | A1 | 8/2015 |
| WO | WO 2015/126743 | A1 | 8/2015 |
| WO | WO 2015/126758 | A1 | 8/2015 |
| WO | WO 2015/126765 | A1 | 8/2015 |
| WO | WO 2015/127003 | A1 | 8/2015 |

OTHER PUBLICATIONS

Naidu et al., U.S. Appl. No. 62/042,300, filed Aug. 27, 2014.

* cited by examiner

*Primary Examiner* — Sun Jae Yoo

(57) **ABSTRACT**

The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.

I




**12 Claims, No Drawings**